17,351 Shares in Boston Scientific Corporation $BSX Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,351 shares of the medical equipment provider’s stock, valued at approximately $750,000.

Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. bought a new stake in Boston Scientific during the second quarter valued at about $5,534,781,000. Primecap Management Co. CA purchased a new position in Boston Scientific in the second quarter worth about $2,156,233,000. Jupiter Topco LLC bought a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $803,357,000. Janus Henderson Group PLC raised its stake in shares of Boston Scientific by 31.0% in the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after acquiring an additional 3,907,981 shares during the period. Finally, Amundi lifted its stake in Boston Scientific by 1.2% in the second quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock worth $610,158,000 after purchasing an additional 173,208 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

BSX opened at $44.67 on Wednesday. The company has a current ratio of 1.36, a quick ratio of 0.81 and a debt-to-equity ratio of 0.42. The firm’s 50-day moving average price is $44.19 and its 200 day moving average price is $55.23. The firm has a market capitalization of $64.74 billion, a PE ratio of 18.93, a PEG ratio of 1.30 and a beta of 0.60. Boston Scientific Corporation has a twelve month low of $39.57 and a twelve month high of $105.65.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.73. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business’s revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Stifel Nicolaus reduced their price target on Boston Scientific from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Jefferies Financial Group lowered shares of Boston Scientific from a “buy” rating to a “hold” rating and decreased their price objective for the company from $60.00 to $46.00 in a research report on Wednesday, October 28th. Finally, The Goldman Sachs Group reduced their target price on Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.